New combo therapy for leukemia patients who Can't have standard chemo
NCT ID NCT06181734
First seen Dec 10, 2025 · Last updated May 15, 2026 · Updated 29 times
Summary
This study looked at how a combination of two drugs, ivosidenib and azacitidine, affects the quality of life and health of adults with a specific type of acute myeloid leukemia (AML) that has an IDH1 mutation. The 8 participants could not receive standard chemotherapy. The main goal was to track their well-being and how well the treatment worked in a real-world setting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Praxis für interdisziplinäre Onkologie & Hämatologie
Freiburg im Breisgau, Germany
Conditions
Explore the condition pages connected to this study.